Skip to main content
. 2020 Jan 9;11(3):537–548. doi: 10.1111/1759-7714.13274

Figure 5.

Figure 5

SOX5 is a target of miR‐219a‐5p in NSCLC cells. (a) The binding sites of miR‐219a‐5p and SOX5 were predicted by TargetScan. (b and c) Luciferase activity was detected in A549 and Calu‐3 cells transfected with SOX5‐WT or SOX5‐MUT and miR‐NC or miR‐219a‐5p. (Inline graphic) miR‐NC and (Inline graphic) miR‐219a‐5p. (dg) The mRNA and protein levels of SOX5 were measured in A549 and Calu‐3 cells transfected with miR‐NC, miR‐219a‐5p, anti‐miR‐NC or anti‐miR‐219a‐5p by qRT‐PCR and western blot. (d, e) (Inline graphic) miR‐NC and (Inline graphic) miR‐219a‐5p. (f, g) (Inline graphic) anti‐miR‐NC and (Inline graphic) anti‐miR‐219a‐5p. (h and i) The expression of SOX5 at mRNA and protein levels was examined in NSCLC tissues and normal tissues (n = 30). (j and k) The mRNA and protein levels of SOX5 were measured in A549 and Calu‐3 cells by qRT‐PCR and western blot. (l) The linear correlation between levels of miR‐219a‐5p and SOX5 in NSCLC tissues was analyzed. *P < 0.05.